Initial Treatment for Claudin-18.2 Positive GE Junction Adenocarcinoma
For claudin-18.2 positive, HER2-negative gastroesophageal junction adenocarcinoma, first-line treatment should be zolbetuximab combined with fluoropyrimidine-platinum chemotherapy (either mFOLFOX6 or CAPOX). 1, 2
Biomarker Testing Requirements
Before initiating treatment, you must confirm:
- CLDN18.2 positivity: Moderate to strong (2+/3+) membranous staining in ≥75% of tumor cells 1
- HER2 status: Must be negative (this is a requirement for zolbetuximab use) 1, 3
- PD-L1 CPS and MSI status: Should also be evaluated as these inform alternative treatment options 3
The 2024 Upper GI Oncology Summit guidelines strongly recommend evaluating all four biomarkers (HER2, PD-L1 CPS, MSI, and claudin 18.2) prior to first-line chemotherapy 3.
Recommended Treatment Regimen
Zolbetuximab plus chemotherapy (Category 1, preferred):
- Zolbetuximab: Initial dose 800 mg/m² followed by 400 mg/m² every 3 weeks
- Plus mFOLFOX6 (oxaliplatin, leucovorin, fluorouracil) OR
- Plus CAPOX (capecitabine, oxaliplatin) 2
This recommendation is based on two landmark Phase III trials (SPOTLIGHT and GLOW) that demonstrated:
- Median overall survival: 18.2 months (SPOTLIGHT) and 14.4 months (GLOW) versus 15.5 and 12.2 months with chemotherapy alone
- Median progression-free survival: 10.6 months (SPOTLIGHT) and 8.2 months (GLOW) versus 8.7 and 6.8 months with chemotherapy alone
- Hazard ratios for death: 0.75 (SPOTLIGHT) and 0.77 (GLOW) 3, 2
Critical Caveats About GEJ-Specific Efficacy
Important limitation: Subgroup analyses from both trials showed reduced benefit in GEJ adenocarcinoma specifically. The hazard ratios for overall survival in GEJ patients were 1.07 (SPOTLIGHT) and 1.01 (GLOW), compared to 0.67/0.72 in gastric adenocarcinoma 3. This suggests zolbetuximab may be less effective for GEJ tumors than for gastric tumors, though it remains the approved standard of care for CLDN18.2-positive disease.
Alternative Consideration: PD-L1 Status
If the tumor is also PD-L1 CPS ≥5, you have two evidence-based options:
- Zolbetuximab plus chemotherapy (as above)
- Nivolumab plus chemotherapy (HR for death 0.82 in GEJ adenocarcinoma) 3, 4
For PD-L1 CPS ≥10, pembrolizumab plus chemotherapy is also an option 4. The choice between CLDN18.2-directed therapy and immunotherapy in dual-positive patients remains an area of active investigation 5, 6.
Practical Management of Toxicity
Anticipate significant gastrointestinal toxicity with zolbetuximab:
- Nausea and vomiting occur in 80-90% of patients (grade ≥3 in 4.8-6.7%) 7, 8
- These events are most prominent during initial treatment cycles, particularly in patients with intact stomachs 8
- Aggressive antiemetic prophylaxis is essential
- Extended observation times and cumbersome administration logistics should be planned for 8
Resectable Disease
For resectable, locally advanced GEJ cancer, the treatment paradigm differs:
- Perioperative chemotherapy or neoadjuvant chemoradiotherapy are weakly recommended 3
- Upfront surgery followed by adjuvant chemotherapy is also acceptable 3
- The role of zolbetuximab in the perioperative setting is not yet established
Biomarker Retesting Considerations
CLDN18.2 expression shows high concordance between primary and metastatic sites 1, but treatment may modulate expression 9. If considering CLDN18.2-directed therapy after progression on zolbetuximab, retesting should be considered though optimal strategies remain undefined 9.